A plaque autoradiography assay to detect and quantitate thymidine kinase (TK) mutants of herpes simplex virus type 1 (HSV-1) and HSV-2 in clinical samples is described. This method utilizes the selective incorporation of Clinical studies with acyclovir (ACV) have stimulated interest in the potential development of antiviral drug resistance and the characterization of herpes simplex virus (HSV) mutants significantly less susceptible to ACV. Although there is no currently established relationship between diminished susceptibility to ACV of an HSV isolate in vitro and lack of response to therapy in vivo for humans and only a preliminary correlation in animals (12), for convenience isolates with significantly reduced susceptibility will be termed "resistant." ACV resistance can be observed in cell culture, and results from the selection of preexisting resistant virus in a mixed population or from the selection of a mutation in the thymidine kinase (TK) or DNA polymnerase locus (4, 14, 37, 40). Both the TK and DNA polymerase loci are involved in the mechanism of action of ACV (4, 11, 14, 37). The TK is responsible for the coflversion of ACV to ACV monophosphate (21), which is subsequently phosphorylated by cellular enzymes to ACV triphosphate (34, 35) . ACV triphosphate then functions as a suicide inactivator of the HSV DNA polymerase (20) , causing premature termination of viral DNA synthesis and the accumulation of short fragments of viral DNA (18, 32) .
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Thus far, only TK mutants have been isolated from clinical samples. However, the term "TK mutant" is misleading; it implies that only thymidine phosphorylation is impaired. In reality, the enzymne is indiscriminant and phosphorylates thymidine (TdR), deoxycytidine, and struc-* Corresponding author. tural analogs of these and other nucleosides (ACV in particular) (6, 9, 24, 25, 27 (8, 29) . Because ACV therapy in certain clinical settings (1, 7, 38) (8, 15, 23) . Mutants S1 and B3 are resistant to ACV and to ACV and E-5(2-bromovinyl)-2'-deoxyuridine, respectively, and encode for TKs with altered substrate specificities (22, 28) . HSV-1 strain CL101 and its TK-mutant B2006 were also obtained from Hugh Field (10) . The KOS strain of HSV-1 and its DNA polymerase mutant PAAI were obtained from Priscilla Schaffer (Dana-Farber Research Center, Boston, Mass.) and have been described previously (2) (3) (4) 17) . AraAg, a polymerase mutant of strain KOS, was obtained from Don Coen (Department of Pharmacology, Harvard Medical School, Boston, Mass.) and has been described previously (3 Ci/mmol) for 2 h at 37°C. After incubation, the label was removed, and the cell monolayers were washed twice with phosphate-buffered saline for 15 min at 37°C. The monolayers were fixed with 10% Formalin in phosphate-buffered saline for 10 min and then stained with 0.8% crystal violet in 95% ethanol. The circumferential rims were removed from the dishes, and the monolayers were placed in contact with Kodak X-Omat XAR-5 X-ray film for 7 days at room temperature. The films were developed, and plaques were scored by the presence of dark or faintly exposed areas on the film that corresponded to plaques on the stained monolayer. The number of dark and faint plaques was compared with the total number of plaques in the stained monolayer to determine the actual percentage of each virus type in the population. Antiviral susceptibility assay. Virus populations were tested for their susceptibility to antiviral drugs by using a standard plaque reduction assay (5). After infection, the plates were overlaid with dilutions of drug contained in 5 ml of Eagle ,MEM supplemented with 5% newborn bovine serum and 0.5% human immune serum globulin. The concentrations of compound required to reduce the plaque numbers by 50% compared with controls lacking drug (ID50s) were obtained by using a computer probability analysis (version 79.3 of procedure PROBIT, Statistical Analysis Systems, Raleigh, N.C.). Virus inhibition assays. The susceptibility of HSV isolates to inhibition by ACV was also determined with a dye uptake assay (33) ethanol. The monolayers, which had been labeled with 125IdC before fixation and staining (see the text), were then placed in contact with X-ray film for 7 days. After the film was developed, autoradiographic foci with an intensity similar to Patton controls were enumerated. Since the TK-virus-infected cells produced no images on the X-ray film, the percent TK+ virus in the mixture was determined. This percent subtracted from 100 represents the observed percent of TK-virus in the mixed population in panel A. TKA virus produce autoradiographic foci with an intensity fainter than Patton; therefore, these foci could be counted directly. The total of the individually calculated ratios of TK+ and TKA virus equaled a total of 100 of the plaques counted on the stained monolayer. The bars represent the standard deviations fronm the mean values obtained from 10 replicates. The calculated values were determined from the known titer of each virus (Patton and B2006) in the defined mixture. Fig. 3 suggest that the reproducible lower limit for the quantitative detection of TK-or TKA virus by this assay method appears to be 10% of the virus population. This value is reflective of the assay-to-assay variation of the autoradiography technique. However, the ability of the assay to detect TK+ revertants in a pure population of TKvirus is much more sensitive, approximately lo-3. This increased sensitivity is illustrated in Fig. 1 , where one TK+ revertant is visible in the field of plaques produced by B2006. From this B2006 TK-stock, 3 TK+ plaques were identified in the 2,157 plaques counted on 10 replicate plates. Susceptibility tests showed a nearly linear relationship between the percentage of the population that is TK-or TKA and the susceptibility of the population to in vitro inhibition by ACV (Fig. 4A and B, respectively) . Extracts were prepared from cells infected with these same reconstructed populations, and the extracts were tested for their ability to phosphorylate ACV (Fig. 5) . Again, there was (Fig. 5A) or TKA (Fig. SB) [14C]TdR readily identifies the TKA virus. These procedures used in tandem will allow the detection of TKA mutants selected during therapy that acquire resistance associated with alterations in substrate specificity or a reduction in the amount of TK.
RESULTS
Viruses resistant to ACV occasionally have emerged during drug therapy, primarily in immunocompromised patients (1, 7, 38) . Thus far, these variants have been identified as either TK-or as TK mutants that express low levels of TK. A virus that may code for a TK with altered substrate specificity has been recovered from a clinical isolate containing a mixed population of viral phenotypes (unpublished data, Table 1 ). This virus was obtained from a patient during chronic suppressive oral ACV therapy. Despite recovery of this TKA virus, the patient healed his lesion normally and continued on suppressive oral drug therapy without further recurrence. After discontinuation of ACV therapy, viruses isolated during recurrences were susceptible to ACV in vitro and contained no TKA virus by plaque autoradiography. Similarly, patients who have shed TK-virus during ACV therapy have generally responded well to continued drug treatment. Viruses from posttherapy recurrences in these patients have also been susceptible to ACV in vitro. Nevertheless, it is important to be able to detect the development of such resistant viruses during the course of therapy, so that when resistant variants do arise, therapy can be modified accordingly. The plaque autoradiography technique described here can be applied directly to clinical samples for the identification and quantitation of TK+, TK-, and TKA virus. Moreover, this method should be useful in studies designed to follow the development of TK mutants in vitro and in vivo. Such studies could provide insight into the role VOL. 28, 1985 on July 8, 2017 by guest http://aac.asm.org/ Downloaded from that the host and the immune status of the host play in the development of clinical resistance.
